ORGANOGENESIS HOLDINGS INC

ORGONASDAQ

🏆 #2831 by market capEarnings Nov 4US Equity

$271.21▼ $19.28 (−7.11%)

Simulated price

1h—

24h▼ 7.1%

7d—

14d—

30d—

1y—

🏦Market Cap

$243M

Small Cap

📈Revenue Growth (YoY)

+12.2%

Healthy

📊Gross Margin

72.9%

High

💵FCF Margin

10.4%

Healthy

⚖️P/S Ratio

0.5x

Cheap

Otter Score

Weak

No chart data available for ORGO.

Trading Snapshot

Day Range: $267.05 – $273.20
52-Week Range: $1.54 – $7.08
Volume: $1.58B
Avg Volume: $1.90B
Shares Outstanding: 128.7M
Next Earnings: Oct 27, 2026

Fundamentals Snapshot

Annual Revenue: $563M
Last Q Revenue: $44M
P/E Ratio: 87.8
P/S Ratio: 0.5x
EPS (TTM): $-0.02
Dividend Yield: —

Why Investors Own ORGO

✓High-growth profile — revenue up +8.8% YoY with expanding US Equity exposure.
✓Healthy economics — 60% gross margin and 24% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$563M▲ +6.6% YoY

Gross Margin (TTM)

59.6%▲ +4.5% YoY

Operating Income (TTM)

$137M▲ +6.6% YoY

Free Cash Flow (TTM)

$132M▲ +6.6% YoY

About ORGANOGENESIS HOLDINGS INC

Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its advanced wound care portfolio, Organogenesis offers several distinct products. These include Affinity and Novachor, both amniotic membrane dressings designed to preserve vital cells, growth factors, and ECM proteins found in natural tissue. Apligraf is a bioengineered living cell therapy that releases a range of healing cytokines and growth factors, while Dermagraft is another bioengineered solution that generates human collagen, ECM, proteins, and cytokines. NuShield provides a wound covering incorporating both amnion and chorion membranes to maintain a spongy intermediate layer. PuraPly acts as an antimicrobial barrier, allowing for flexibility and effective fluid drainage. For the surgical and sports medicine sectors, the company provides products such as NuCel, a dehydrated placental tissue designed for surgical application to promote natural tissue regeneration. ReNu is a cryopreserved suspension aimed at aiding soft tissue recovery. Additionally, FiberOS and OCMP serve as bone void fillers, primarily utilized in orthopedic and neurosurgical procedures. Looking ahead, Organogenesis's product pipeline features PuraPly XT and PuraPly MZ, which are being developed for treating chronic, acute, and open wounds. PuraForce is a bioengineered porcine collagen surgical matrix intended for soft tissue reinforcement. TransCyte, another bioengineered tissue, is in development for addressing partial thickness burns. Organogenesis distributes its offerings to a diverse client base, including hospitals, specialized wound care centers, government institutions, ambulatory surgical centers, and physician offices, leveraging both its direct sales team and independent agencies. Established in 1985, the company maintains its headquarters in Canton, Massachusetts.

🦦